Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
Portfolio Pulse from
Johnson & Johnson announced positive Phase 3 results for icotrokinra (JNJ-2113), a first-in-class oral peptide for treating moderate to severe plaque psoriasis. The study showed 74% of patients achieved clear or almost clear skin at week 24.
November 18, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's icotrokinra (JNJ-2113) achieved significant results in a Phase 3 study for plaque psoriasis, with 74% of patients showing clear or almost clear skin. This could enhance JNJ's product portfolio and market position.
The successful Phase 3 results for icotrokinra, a novel treatment for plaque psoriasis, could lead to a new product offering for JNJ, potentially increasing their market share and revenue. The high efficacy rate of 74% achieving clear skin is a strong indicator of the drug's potential success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100